Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study

[1]  Graham Knight,et al.  Measures of Socioeconomic Status , 2021 .

[2]  R. Ofori-Asenso,et al.  Patterns of statin use and long‐term adherence and persistence among older adults with diabetes , 2018, Journal of diabetes.

[3]  P. Thompson,et al.  The effects of statins on exercise and physical activity. , 2017, Journal of clinical lipidology.

[4]  J. Shaw,et al.  Diabetes and disability in older Australians: The Australian Diabetes, Obesity and Lifestyle (AusDiab) study. , 2017, Diabetes research and clinical practice.

[5]  D. Magliano,et al.  Do statin users adhere to a healthy diet and lifestyle? The Australian Diabetes, Obesity and Lifestyle Study , 2017, European journal of preventive cardiology.

[6]  I. Scott,et al.  National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016 , 2016, The Medical journal of Australia.

[7]  I. Scott,et al.  National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. , 2016, Heart, lung & circulation.

[8]  Sandeep K. Krishnan,et al.  Statins in the Elderly: A Patient‐Focused Approach , 2015, Clinical cardiology.

[9]  E. Roughead,et al.  Use of Statins in an Australian Elderly Population , 2014 .

[10]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2014, Journal of the American Pharmacists Association : JAPhA.

[11]  Susan T. Shero,et al.  2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[12]  S. Ebrahim,et al.  Statins for the primary prevention of cardiovascular disease , 2014, BMJ : British Medical Journal.

[13]  M. Falster,et al.  Factors influencing adherence in long‐term use of statins , 2013, Pharmacoepidemiology and drug safety.

[14]  Mark D. Huffman,et al.  Statins for the primary prevention of cardiovascular disease. , 2013, The Cochrane database of systematic reviews.

[15]  J. Kaufman,et al.  Relationship between alcohol consumption and myocardial infarction among ageing men using a marginal structural model. , 2012, European journal of public health.

[16]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[17]  L. Hogg.  Executive Working Group , 2009 .

[18]  J. Shaw,et al.  Validity of self‐reported cardiovascular disease events in comparison to medical record adjudication and a statewide hospital morbidity database: the AusDiab study , 2009, Internal medicine journal.

[19]  A. Tonkin,et al.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. , 2005 .

[20]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[21]  Ralph B D'Agostino,et al.  Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. , 2005, Alcoholism, clinical and experimental research.

[22]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[23]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[24]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  J. Shaw,et al.  The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)--methods and response rates. , 2002, Diabetes research and clinical practice.

[26]  Amanda J. Patterson,et al.  The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle‐aged women in a study of iron supplementation , 2000, Australian and New Zealand journal of public health.

[27]  G Corrao,et al.  Alcohol and coronary heart disease: a meta-analysis. , 2000, Addiction.

[28]  V. Fuster,et al.  AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Journal of the American College of Cardiology.

[29]  Philip Greenland,et al.  Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations , 1999 .

[30]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[31]  A. Dobson,et al.  How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event , 1997, BMJ.

[32]  I. Puddey,et al.  Alcohol, hypertension and the cardiovascular system: a critical appraisal , 1997, Addiction biology.

[33]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[34]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[35]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[36]  I. Puddey,et al.  Alcohol, hypertension and cardiovascular disease--implications for management. , 1993, Clinical and experimental hypertension.

[37]  R. Beaglehole,et al.  Alcohol consumption and risk of coronary heart disease , 1991, BMJ.

[38]  Adrian Bauman,et al.  Habitual physical activity and cardiovascular risk factors , 1991 .

[39]  G. Miller,et al.  Alcohol consumption: protection against coronary heart disease and risks to health. , 1990, International journal of epidemiology.

[40]  W. Kannel,et al.  Diet and its relation to coronary heart disease. , 1981, Circulation.

[41]  N. Ernst,et al.  Alcohol and High‐density Lipoprotein Cholesterol , 1981, Circulation.

[42]  W. Castelli,et al.  ALCOHOL AND BLOOD LIPIDS The Cooperative Lipoprotein Phenotyping Study , 1977, The Lancet.

[43]  Jonathan E. Dickerson,et al.  Supplementary webappendix , 2013 .

[44]  F. Catalá-López,et al.  PHARMACOEPIDEMIOLOGYAND PRESCRIPTION Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study , 2013 .

[45]  Eur J Clin Pharmacol.  Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study , 2013 .

[46]  K. Brussen.  The Australian Guidelines to Reduce Health Risks from Drinking Alcohol , 2010 .